Calamos Advisors’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Calamos Advisors’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-322,682	Closed	-$39.1M	–	1159
2023 Q1	$39.1M	Sell	322,682 -258	-0.1%	-$29.7K	0.19%	133
2022 Q4	$37.1M	Sell	322,940 -76	-0%	-$8.38K	0.17%	155
2022 Q3	$32.7M	Sell	323,016 -93,639	-22%	-$9.9M	0.15%	171
2022 Q2	$42.3M	Buy	416,655 +31,039	+8%	+$3.38M	0.18%	136
2022 Q1	$44.9M	Sell	385,616 -2,958	-0.8%	-$342K	0.17%	146
2021 Q4	$44.6M	Buy	+388,574	New	+$44.3M	0.17%	143
2021 Q1	–	Sell	-484,157	Closed	-$53M	–	982
2020 Q4	$53M	Sell	484,157 -69,082	-12%	-$7.48M	0.31%	80
2020 Q3	$61.9M	Sell	553,239 -16,677	-3%	-$1.87M	0.4%	51
2020 Q2	$59.7M	Buy	+569,916	New	+$61M	0.42%	49

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Calamos Advisors's BSX.PRA Position: Q2 2023 in Review

Calamos Advisors sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 322,682 shares — an estimated $39.1M sold.

Calamos Advisors first reported a position in BSX.PRA in Q2 2020 and held it in 9 quarters. The position peaked at $61.9M in Q3 2020. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

Calamos Advisors reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
Calamos Advisors sold 322,682 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $39.1M.
Calamos Advisors first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 9 quarters.
Calamos Advisors's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $61.9M in Q3 2020.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Calamos Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.